{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:52:26Z","timestamp":1784829146437,"version":"3.55.0"},"reference-count":93,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Diabetes mellitus is a long-lasting disease that is very common in the age group above\n20 years and is characterized by hyperglycemia with other complications like Diabetic Nephropathy\n(DN). The management of DN focuses on mainly four regions: reduction of cardiovascular\nrisks, control of blood glycemic levels, control of the blood pressure (BP) profile, and the use of\ntherenin-angiotensin system (RAS). Although BP management and RAS-acting agents can postpone\nthe onset of DN, they cannot prevent it. In the modern era, nanotechnological interventions\nhave spread rapidly in the field of medicine. Patient defiance is considered important in diabetes\nmanagement when long-term or continuous management is required. Nano pharmaceuticals have\nbeen shown to increase compliance of diabetic patients by providing multiple ways of drug delivery,\ncontrolling release profile, increasing biological steadiness, targeting efficacy, and decreasing\ntoxic profile. Nanoscale formulations of botanical antidiabetic molecules improve clinical efficacy\nand treatment compliance by overcoming associated biopharmaceutical and pharmacokinetic barriers.\nTherefore, the development of nanopharmaceuticals can be considered to be a possible answer\nto attain the finest scientific effect of the plant-based anti-diabetic molecule. Nevertheless, further\nstudies are needed to create clinical research-based and therapeutically effective nanoforms of antidiabetic\nplant-based molecules to combat the most dreaded disease of diabetes and its known present\ncomplications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450124666230601163338","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:33:58Z","timestamp":1685702038000},"page":"662-672","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nano Architect-Based Targeted Delivery Systems for Diabetic Nephropathy:\nA Review"],"prefix":"10.2174","volume":"24","author":[{"given":"Aruna","family":"Rawat","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Science, School of Medical and Allied Science, GD Goenka University, Gurugram,\nHaryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-9636","authenticated-orcid":true,"given":"Vikas","family":"Jhawat","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, School of Medical and Allied Science, GD Goenka University, Gurugram,\nHaryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Dutt","sequence":"additional","affiliation":[{"name":"Gandhi Memorial National College, Ambala Cantt., Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.15585\/mmwr.mm6906a3","volume":"69","author":"Divers J.","year":"2020","unstructured":"Divers J.; Mayer-Davis E.J.; Lawrence J.M.; Isom S.; Dabelea D.; Dolan L.; Imperatore G.; Marcovina S.; Pettitt D.J.; Pihoker C.; Hamman R.F.; Saydah S.; Wagenknecht L.E.; Trends in incidence of type 1 and type 2 diabetes among youths-selected counties and Indian reservations, United States, 2002\u20132015. MMWR Morb Mortal Wkly Rep 2020,69(6),161-165","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"Rawshani A.","year":"2017","unstructured":"Rawshani A.; Rawshani A.; Franz&#xE9;n S.; Eliasson B.; Svensson A.M.; Miftaraj M.; McGuire D.K.; Sattar N.; Rosengren A.; Gudbj&#xF6;rnsdottir S.; Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017,376(15),1407-1418","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"Li H.","year":"2021","unstructured":"Li H.; Lu W.; Wang A.; Jiang H.; Lyu J.; Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J Diabetes Investig 2021,12(3),346-356","journal-title":"J Diabetes Investig"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0272-6386(04)01079-0","volume":"44","author":"Tapp R.J.","year":"2004","unstructured":"Tapp R.J.; Shaw J.E.; Zimmet P.Z.; Balkau B.; Chadban S.J.; Tonkin A.M.; Welborn T.A.; Atkins R.C.; Albuminuria is evident in the early stages of diabetes onset: Results from the Australian diabetes, obesity, and lifestyle study (AusDiab). Am J Kidney Dis 2004,44(5),792-798","journal-title":"Am J Kidney Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.vph.2013.01.001","volume":"58","author":"Arora M.K.","year":"2013","unstructured":"Arora M.K.; Singh U.K.; Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update. Vascul Pharmacol 2013,58(4),259-271","journal-title":"Vascul Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"671566","DOI":"10.3389\/fendo.2021.671566","volume":"12","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Shan S.K.; Guo B.; Li F.; Zheng M.H.; Lei L.M.; Xu Q.S.; Ullah M.H.E.; Xu F.; Lin X.; Yuan L.Q.; The multi-therapeutic role of MSCs in diabetic nephropathy. Front Endocrinol (Lausanne) 2021,12,671566","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"22","author":"Selby N.M.","year":"2020","unstructured":"Selby N.M.; Taal M.W.; An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 2020,22(S1)(Suppl. 1),3-15","journal-title":"Diabetes Obes Metab"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10557-017-6755-9","volume":"31","author":"Magee C.","year":"2017","unstructured":"Magee C.; Grieve D.J.; Watson C.J.; Brazil D.P.; Diabetic nephropathy: A tangled web to unweave. Cardiovasc Drugs Ther 2017,31(5-6),579-592","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.phrs.2018.09.012","volume":"136","author":"Parsamanesh N.","year":"2018","unstructured":"Parsamanesh N.; Moossavi M.; Bahrami A.; Butler A.E.; Sahebkar A.; Therapeutic potential of curcumin in diabetic complications. Pharmacol Res 2018,136,181-193","journal-title":"Pharmacol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000505145","volume":"51","author":"Jiang S.","year":"2020","unstructured":"Jiang S.; Fang J.; Yu T.; Liu L.; Zou G.; Gao H.; Novel model predicts diabetic nephropathy in type 2 diabetes. Am J Nephrol 2020,51(2),130-138","journal-title":"Am J Nephrol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"697010","DOI":"10.1155\/2015\/697010","volume":"2015","author":"Toth-Manikowski S.","year":"2015","unstructured":"Toth-Manikowski S.; Atta M.G.; Diabetic kidney disease: Pathophysiology and therapeutic targets. J Diabetes Res 2015,2015,697010","journal-title":"J Diabetes Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/IJNRD.S40172","volume":"7","author":"Lim A.K.","year":"2021","unstructured":"Lim A.K.; Diabetic nephropathy-Complications, and treatment. Int J Nephrol Renovasc Dis 2021,7,361-381","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1042\/CS20160636","volume":"131","author":"Tesch G.H.","year":"2017","unstructured":"Tesch G.H.; Diabetic nephropathy-Is this an immune disorder? Clin Sci (Lond) 2017,131(16),2183-2199","journal-title":"Clin Sci (Lond)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jdi.12319","volume":"6","author":"Haneda M.","year":"2015","unstructured":"Haneda M.; Utsunomiya K.; Koya D.; Babazono T.; Moriya T.; Makino H.; Kimura K.; Suzuki Y.; Wada T.; Ogawa S.; Inaba M.; Kanno Y.; Shigematsu T.; Masakane I.; Tsuchiya K.; Honda K.; Ichikawa K.; Shide K.; A new classification of diabetic nephropathy 2014: A report from joint committee on diabetic nephropathy. J Diabetes Investig 2015,6(2),242-246","journal-title":"J Diabetes Investig"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2215\/CJN.01650216","volume":"12","author":"Cabrera V.J.","year":"2017","unstructured":"Cabrera V.J.; Hansson J.; Kliger A.S.; Finkelstein F.O.; Symptom management of the patient with CKD: The role of dialysis. Clin J Am Soc Nephrol 2017,12(4),687-693","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.sjbs.2014.04.005","volume":"22","author":"Banu S.","year":"2015","unstructured":"Banu S.; Jabir N.R.; Manjunath N.C.; Khan M.S.; Ashraf G.M.; Kamal M.A.; Tabrez S.; Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J Biol Sci 2015,22(1),32-36","journal-title":"Saudi J Biol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/ijms21010263","volume":"21","author":"Rapa SF","year":"2019","unstructured":"Rapa SF; Di Iorio BR; Campiglia P; Heidland A; Marzocco S; Inflammation and oxidative stress in chronic kidney disease\u2014potential therapeutic role of minerals, vitamins, and plant-derived metabolites. Int J Mol Sci 2019,21(1),263","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.3390\/md12063292","volume":"12","author":"Wang J.","year":"2014","unstructured":"Wang J.; Liu H.; Li N.; Zhang Q.; Zhang H.; The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy. Mar Drugs 2014,12(6),3292-3306","journal-title":"Mar Drugs"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2147\/DMSO.S380550","volume":"15","author":"Liu C.","year":"2022","unstructured":"Liu C.; Wu K.; Gao H.; Li J.; Xu X.; Current strategies and potential prospects for nanoparticle-mediated treatment of diabetic nephropathy. Diabetes Metab Syndr Obes 2022,15,2653-2673","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"870049","DOI":"10.3389\/fbioe.2022.870049","volume":"10","author":"Lin B.","year":"2022","unstructured":"Lin B.; Ma Y.Y.; Wang J.W.; Nano-technological approaches for targeting kidney diseases with a focus on diabetic nephropathy: Recent progress and future perspectives. Front Bioeng Biotechnol 2022,10,870049","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"805978","DOI":"10.3389\/fonc.2022.805978","volume":"12","author":"Wu K.","year":"2022","unstructured":"Wu K.; Yu B.; Li D.; Tian Y.; Liu Y.; Jiang J.; Recent advances in nanoplatforms for the treatment of osteosarcoma. Front Oncol 2022,12(12),805978","journal-title":"Front Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.2523\/IPTC-17857-MS","author":"Martin V.","year":"2014","unstructured":"Martin V.; Bennetzen K.M.; Novel applications of nanoparticles for future enhanced oil recovery. Paper presented at the International Petroleum Technology Conference 2014","journal-title":"Paper presented at the International Petroleum Technology Conference"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"Anselmo A.C.","year":"2019","unstructured":"Anselmo A.C.; Mitragotri S.; Nanoparticles in the clinic: An update. Bioeng Transl Med 2019,4(3),e10143","journal-title":"Bioeng Transl Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1038\/s41598-020-66098-3","volume":"10","author":"Bo Cui F.G.","year":"2020","unstructured":"Bo Cui F.G.; Zeng Z.; Wang C.; Wang Y.; Sun C.; Zhao X.; Guo L.; Shen Y.; Liu G.; Cui X.; Construction and characterization of avermectin B2 solid nanodispersion. Sci Rep 2020,10(1),9096","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.3390\/ma12203355","volume":"12","author":"Leitner J.","year":"2019","unstructured":"Leitner J.; Sedmidubsk&#xFD; D.; Jankovsk&#xFD; O.; Size and shape-dependent solubility of CuO nanostructures. Materials (Basel) 2019,12(20),3355","journal-title":"Materials (Basel)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1039\/C8RA08284G","volume":"9","author":"Li S.","year":"2019","unstructured":"Li S.; Sun K.; Zhao Y.; Nie G.; Song S.; Purification and rapid dissolution of potassium sulfate in aqueous solutions. RSC Advances 2019,9(4),2156-2161","journal-title":"RSC Advances"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1021\/acs.jafc.8b01388","volume":"66","author":"Guan W.","year":"2018","unstructured":"Guan W.; Tang L.; Wang Y.; Cui H.; Fabrication of an effective avermectin nanoemulsion using a cleavable succinic ester emulsifier. J Agric Food Chem 2018,66(29),7568-7576","journal-title":"J Agric Food Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S2211-9477(12)70005-5","volume":"1","author":"Vinod P.B.","year":"2012","unstructured":"Vinod P.B.; Pathophysiology of diabetic nephropathy. Clin Queries Nephrol 2012,1(2),121-126","journal-title":"Clin Queries Nephrol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/dom.12630","volume":"18","author":"Gallagher H.","year":"2016","unstructured":"Gallagher H.; Suckling R.J.; Diabetic nephropathy: Where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab 2016,18(7),641-647","journal-title":"Diabetes Obes Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1681\/ASN.2005121324","volume":"17","author":"Giuseppe Remuzzi","year":"2006","unstructured":"Giuseppe Remuzzi; Manuel M; Ruggenenti P; Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J Am Soc Nephrol 2006,17(4(Supp2)),S90-S97","journal-title":"J Am Soc Nephrol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-93521-8_2","author":"Frimodt-M&#xF8;ller M.","year":"2019","unstructured":"Frimodt-M&#xF8;ller M.; Rossing P.; Clinical features and natural course of diabetic nephropathy diabetic nephropathy. Diabetic Nephropathy 2019,21-32","journal-title":"Diabetic Nephropathy"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fphys.2017.00211","volume":"8","author":"Schiffer T.A.","year":"2017","unstructured":"Schiffer T.A.; Friederich-Persson M.; Mitochondrial reactive oxygen species and kidney hypoxia in the development of diabetic nephropathy. Front Physiol 2017,8(8),211","journal-title":"Front Physiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/1354750X.2018.1501761","volume":"24","author":"Fathy S.A.","year":"2019","unstructured":"Fathy S.A.; Mohamed M.R.; Ali M.A.M.; Influence of IL-6, IL-10, IFN-&#x3B3;, and TNF-&#x3B1; genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers 2019,24(1),43-55","journal-title":"Biomarkers"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1134\/S2079057012010122","volume":"2","author":"Ryabova T.S.","year":"2012","unstructured":"Ryabova T.S.; Rakityanskaya I.A.; The effects of IL6 cytokine expression in renal tissue on the clinical and morphological picture of iganephropathy in patients over 60 years old. Adv Gerontol 2012,2(2),244-248","journal-title":"Adv Gerontol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1748-1716.2006.01582.x","volume":"187","author":"Mount P.F.","year":"2006","unstructured":"Mount P.F.; Power D.A.; Nitric oxide in the kidney: Functions and regulation of synthesis. Acta Physiol (Oxf) 2006,187(4),433-446","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14728222.2019.1624721","volume":"23","author":"Warren A.M.","year":"2019","unstructured":"Warren A.M.; Knudsen S.T.; Cooper M.E.; Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets 2019,23(7),579-591","journal-title":"Expert Opin Ther Targets"},{"key":"ref=37","author":"Harvey M.","year":"2014","unstructured":"Harvey M.; Restriction of combined use of medicines affecting the renin-angiotensin system (RAS). European Medicines Agency Available from: 2014","journal-title":"European Medicines Agency"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","volume":"71","author":"Umanath K.","year":"2018","unstructured":"Umanath K.; Lewis J.B.; Update on diabetic nephropathy: Core curriculum 2018. Am J Kidney Dis 2018,71(6),884-895","journal-title":"Am J Kidney Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"Heerspink H.J.L.","year":"2016","unstructured":"Heerspink H.J.L.; Perkins B.A.; Fitchett D.H.; Husain M.; Cherney D.Z.I.; Sodium-glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016,134(10),752-772","journal-title":"Circulation"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"Linda F.","year":"2013","unstructured":"Linda F.; Fried N.E.; Jane H.; Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013,369(20),1892-1903","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.phymed.2018.04.039","volume":"43","author":"Abdel-Magid AD","year":"2017","unstructured":"Abdel-Magid AD; Mohamed Abou-Salem ES; Nancy Salaam MHA; El-Garhy HAS; The potential effect of garlic extract and curcumin nanoparticles against complications accompanied with experimentally induced diabetes in rats. Phytomedicine 2017,43,126-134","journal-title":"Phytomedicine"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.carbpol.2015.10.021","volume":"136","author":"D\u2019Souza A.A.","year":"2016","unstructured":"D\u2019Souza A.A.; Devarajan P.V.; Bioenhanced oral curcumin nanoparticles: Role of carbohydrates. Carbohydr Polym 2016,136,1251-1258","journal-title":"Carbohydr Polym"},{"key":"ref=43","first-page":"97","volume":"76","author":"Dodda D.","year":"2014","unstructured":"Dodda D.; Ciddi V.; Plants used in the management of diabetic complications. Indian J Pharm Sci 2014,76(2),97-106","journal-title":"Indian J Pharm Sci"},{"key":"ref=44","first-page":"2320","volume":"8","author":"Tiwari R.K.","year":"2019","unstructured":"Tiwari R.K.; Sharma A.; Pandey R.K.; Shukla S.S.; A review on mechanism and plants used for diabetic nephropathy: A curse of diabetes. Mintage J Pharmaceut Med Sci 2019,8(4),2320-3315","journal-title":"Mintage J Pharmaceut Med Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"003","DOI":"10.4172\/2167-0412.S2-003","volume":"Suppl 2","author":"Tsabang N.","year":"2015","unstructured":"Tsabang N.; Yedjou C.G.; Tsambang L.; Treatment of diabetes and\/or hypertension using medicinal plants in Cameroon. Med Aromat Plants 2015,Suppl 2,003","journal-title":"Med Aromat Plants"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/03639045.2020.1862173","volume":"47","author":"Han J.","year":"2020","unstructured":"Han J.; Tong M.; Yu X.; Surfactant-free amorphous solid dispersion with high dissolution for bioavailability enhancement of hydrophobic drugs: A case of quercetin. Drug Dev Ind Pharm 2020,47(1),153-162","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","volume":"2","year":"2014","unstructured":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014,2(10),793-800","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"s28","DOI":"10.2337\/diacare.26.2007.S28","volume":"26","author":"Genuth S.","year":"2003","unstructured":"Genuth S.; Eastman R.; Kahn R.; Klein R.; Lachin J.; Lebovitz H.; Nathan D.; Vinicor F.; Implications of the United kingdom prospective diabetes study. Diabetes Care 2003,26(Suppl. 1),s28-s32","journal-title":"Diabetes Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"Brenner B.M.","year":"2001","unstructured":"Brenner B.M.; Cooper M.E.; de Zeeuw D.; Keane W.F.; Mitch W.E.; Parving H.H.; Remuzzi G.; Snapinn S.M.; Zhang Z.; Shahinfar S.; Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001,345(12),861-869","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"Lewis E.J.","year":"2001","unstructured":"Lewis E.J.; Hunsicker L.G.; Clarke W.R.; Berl T.; Pohl M.A.; Lewis J.B.; Ritz E.; Atkins R.C.; Rohde R.; Raz I.; Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001,345(12),851-860","journal-title":"N Engl J Med"},{"key":"ref=51","first-page":"503","volume":"90","author":"Armstrong C.","year":"2014","unstructured":"Armstrong C.; JNC8 guidelines for the management of hypertension in adults. Am Fam Physician 2014,90(7),503-504","journal-title":"Am Fam Physician"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e000810","DOI":"10.1161\/JAHA.114.000810","volume":"3","author":"Menne J.","year":"2014","unstructured":"Menne J.; Ritz E.; Ruilope L.M.; Chatzikyrkou C.; Viberti G.; Haller H.; The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc 2014,3(2),e000810","journal-title":"J Am Heart Assoc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"870049","DOI":"10.3389\/fbioe.2022.870049","volume":"10","author":"Lin B.","year":"2022","unstructured":"Lin B.; Ma Y.Y.; Wang J.W.; Nanotechnological Approaches for targetting kidney diseases with a focus on diabetic nephropathy: Recent progress, and future perspectives. Front Bioeng Biotechnol 2022,10,870049","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.3390\/app11167187","volume":"11","author":"Hauser P.V.","year":"2021","unstructured":"Hauser P.V.; Chang H.M.; Yanagawa N.; Hamon M.; Nanotechnology, Nanomedicine, and the Kidney. Appl Sci (Basel) [Review].2021,11(16),7187","journal-title":"Appl Sci (Basel)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"119674","DOI":"10.1016\/j.lfs.2021.119674","volume":"279","author":"Khater S.I.","year":"2021","unstructured":"Khater S.I.; Mohamed A.A.R.; Arisha A.H.; Ebraheim L.L.M.; El-Mandrawy S.A.M.; Nassan M.A.; Mohammed A.T.; Abdo S.A.; Stabilized-chitosan selenium nanoparticles efficiently reduce renal tissue injury and regulate the expression pattern of aldose reductase in the diabetic-nephropathy rat model. Life Sci 2021,279,119674","journal-title":"Life Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris GL","year":"2015","unstructured":"Bakris GL; Agarwal R; Chan JC; Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015,314(9),884-894","journal-title":"JAMA"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s13300-017-0320-1","volume":"8","author":"Rastogi A.","year":"2017","unstructured":"Rastogi A.; Bhansali A.; SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: A review. Diabetes Ther 2017,8(6),1245-1251","journal-title":"Diabetes Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1111\/bph.13816","volume":"174","author":"Ganugula R.","year":"2017","unstructured":"Ganugula R.; Arora M.; Jaisamut P.; Wiwattanapatapee R.; J&#xF8;rgensen H.G.; Venkatpurwar V.P.; Zhou B.; Rodrigues Hoffmann A.; Basu R.; Guo S.; Majeti N.V.R.K.; Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. Br J Pharmacol 2017,174(13),2074-2084","journal-title":"Br J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.toxrep.2019.09.003","volume":"6","author":"Adewale O.O.","year":"2019","unstructured":"Adewale O.O.; Samuel E.S.; Manubolu M.; Pathakoti K.; Curcumin protects sodium nitrite-induced hepatotoxicity in Wistar rats. Toxicol Rep 2019,6,1006-1011","journal-title":"Toxicol Rep"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4314\/ajtcam.v5i4.31291","volume":"5","author":"Kaya I.","year":"2008","unstructured":"Kaya I.; Yi&#x11F;it N.; Benli M.; Antimicrobial activity of various extracts of Ocimum basilicum and observation of the inhibition effect on bacterial cells by use of scanning electron microscopy. Afr J Tradit Complement Altern Med 2008,5(4),363-369","journal-title":"Afr J Tradit Complement Altern Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.15228\/2013.v03.i01.p02","volume":"3","author":"Khair-ul-Bariyah S.","year":"2013","unstructured":"Khair-ul-Bariyah S.; An extensive survey of the phytochemistry and therapeutic potency of Ocimum sanctum (Queen of Herbs). Pak J Chem 2013,3(1),8-18","journal-title":"Pak J Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/molecules25010112","volume":"25","author":"Bayda S.","year":"2020","unstructured":"Bayda S.; Adeel M.; Tuccinardi T.; Cordan M.; Rizzolio F.; The history of nanoscience and nanotechnology: From chemical\u2013physical applications to nanomedicine. Molecules 2020,25(1),112","journal-title":"Molecules"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10311-018-00841-1","volume":"17","author":"Chamundeeswari M.","year":"2019","unstructured":"Chamundeeswari M.; Jeslin J.; Verma M.L.; Nanocarriers for drug delivery applications. Environ Chem Lett 2019,17(2),849-865","journal-title":"Environ Chem Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/2468187308666180501092519","volume":"8","author":"Girdhar V.","year":"2018","unstructured":"Girdhar V.; Patil S.; Banerjee S.; Singhvi G.; Nanocarriers for drug delivery: Mini review. Curr Nanomed 2018,8(2),88-99","journal-title":"Curr Nanomed"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","volume":"15","author":"Hossen S.","year":"2019","unstructured":"Hossen S.; Hossain M.K.; Basher M.K.; Mia M.N.H.; Rahman M.T.; Uddin M.J.; Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J Adv Res 2019,15,1-18","journal-title":"J Adv Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejps.2017.10.012","volume":"111","author":"Ahad A.","year":"2018","unstructured":"Ahad A.; Raish M.; Ahmad A.; Al-Jenoobi F.I.; Al-Mohizea A.M.; Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharm Sci 2018,111,409-417","journal-title":"Eur J Pharm Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1039\/C9TB00170K","volume":"7","author":"Zhang M.","year":"2019","unstructured":"Zhang M.; Zang X.; Wang M.; Li Z.; Qiao M.; Hu H.; Chen D.; Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J Mater Chem B Mater Biol Med 2019,7(15),2421-2433","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrd4477","volume":"14","author":"Veiseh O.","year":"2015","unstructured":"Veiseh O.; Tang B.C.; Whitehead K.A.; Anderson D.G.; Langer R.; Managing diabetes with nanomedicine: Challenges and opportunities. Nat Rev Drug Discov 2015,14(1),45-57","journal-title":"Nat Rev Drug Discov"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","volume":"116","author":"des Rieux A","year":"2006","unstructured":"des Rieux A; Fievez V; Guerinot M; Schneider YJ; Pr&#xE9;at V; Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 2006,116(1),1-27","journal-title":"J Control Release"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.omtn.2020.01.034","volume":"20","author":"Chakraborty S.","year":"2020","unstructured":"Chakraborty S.; Dlie Z.Y.; Chakraborty S.; Roy S.; Mukherjee B.; Besra S.E.; Dewanjee S.; Mukherjee A.; Ojha P.K.; Kumar V.; Sen R.; Aptamer-functionalized drug nanocarrier improves hepatocellular carcinoma toward normal by targeting neoplastic hepatocytes. Mol Ther Nucleic Acids 2020,20,34-49","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.7150\/thno.37538","volume":"9","author":"Wang G.","year":"2019","unstructured":"Wang G.; Li Q.; Chen D.; Wu B.; Wu Y.; Tong W.; Huang P.; Kidney-targeted rhein-loaded liponanoparticles for diabetic nephropathy therapy via size control and enhancement of renal cellular uptake. Theranostics 2019,9(21),6191-6208","journal-title":"Theranostics"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jim-2016-000272","volume":"65","author":"Prabhakar SS","year":"2016","unstructured":"Prabhakar SS; Effects of curcumin in experimental diabetic nephropathy. J Investig Med 2016,65(1),1-6","journal-title":"J Investig Med"},{"key":"ref=73","first-page":"444","volume":"12","author":"Mitra R.","year":"2019","unstructured":"Mitra R.; Kaura K.; Kaushik P.; Renoprotective effect of nanoformulation of taurine in streptozotocin induced diabetic nephropathy in wistar rats. PAIDEUMA J 2019,12(12),444-461","journal-title":"PAIDEUMA J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12951-021-00917-1","volume":"19","author":"Huang C.","year":"2021","unstructured":"Huang C.; Xue L.F.; Hu B.; Liu H.H.; Huang S.B.; Khan S.; Meng Y.; Calycosin-loaded nanoliposomes as potential nanoplatforms for treatment of diabetic nephropathy through regulation of mitochondrial respiratory function. J Nanobiotechnology 2021,19(1),178","journal-title":"J Nanobiotechnology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/10717544.2019.1642417","volume":"26","author":"Yang X.","year":"2019","unstructured":"Yang X.; Design and optimization of crocetin loaded PLGA nanoparticles against diabetic nephropathy via suppression of inflammatory biomarkers: A formulation approach to preclinical study. Drug Deliv 2019,26(1),849-859","journal-title":"Drug Deliv"},{"key":"ref=76","first-page":"1424","volume":"22","author":"Ahangarpour A.","year":"2019","unstructured":"Ahangarpour A.; Oroojan A.A.; Khorsandi L.; Kouchak M.; Badavi M.; Antioxidant, anti-apoptotic, and protective effects of myricitrin and its solid lipid nanoparticle on streptozotocin-nicotinamide-induced diabetic nephropathy in type 2 diabetic male mice. Iran J Basic Med Sci 2019,22(12),1424-1431","journal-title":"Iran J Basic Med Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"103007","DOI":"10.1016\/j.arabjc.2021.103007","volume":"14","author":"Yu Y.","year":"2021","unstructured":"Yu Y.; Gao J.; Jiang L.; Wang J.; Antidiabetic nephropathy effects of synthesized gold nanoparticles through mitigation of oxidative stress. Arab J Chem 2021,14(3),103007","journal-title":"Arab J Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.carbpol.2018.04.011","volume":"193","author":"Hu J.B.","year":"2018","unstructured":"Hu J.B.; Li S.J.; Kang X.Q.; Qi J.; Wu J.H.; Wang X.J.; Xu X.L.; Ying X.Y.; Jiang S.P.; You J.; Du Y.Z.; CD44-targeted hyaluronic acid-curcumin prodrug protects renal tubular epithelial cell survival from oxidative stress damage. Carbohydr Polym 2018,193,268-280","journal-title":"Carbohydr Polym"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijpharm.2015.04.067","volume":"489","author":"Allam A.N.","year":"2015","unstructured":"Allam A.N.; Komeil I.A.; Fouda M.A.; Abdallah O.Y.; Preparation, characterization and in vivo evaluation of curcumin self-nano phospholipid dispersion as an approach to enhance oral bioavailability. Int J Pharm 2015,489(1-2),117-123","journal-title":"Int J Pharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s42269-019-0164-0","volume":"43","author":"Gouda W.","year":"2019","unstructured":"Gouda W.; Hafiz N.A.; Mageed L.; Alazzouni A.S.; Khalil W.K.B.; Afify M.; Abdelmaksoud M.D.E.; Effects of nano-curcumin on gene expression of insulin and insulin receptor. Bull Natl Res Cent 2019,43(1),128","journal-title":"Bull Natl Res Cent"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2147\/IJN.S153763","volume":"13","author":"Tong F.","year":"2018","unstructured":"Tong F.; Chai R.; Jiang H.; Dong B.; in vitro\/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin\/PBLG-PEG-PBLG nanoparticles. Int J Nanomedicine 2018,13,1945-1962","journal-title":"Int J Nanomedicine"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/jf202135j","volume":"59","author":"Xie X.","year":"2011","unstructured":"Xie X.; Tao Q.; Zou Y.; Zhang F.; Guo M.; Wang Y.; Wang H.; Zhou Q.; Yu S.; PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 2011,59(17),9280-9289","journal-title":"J Agric Food Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.nano.2013.01.001","volume":"9","author":"Joshi R.P.","year":"2013","unstructured":"Joshi R.P.; Negi G.; Kumar A.; Pawar Y.B.; Munjal B.; Bansal A.K.; Sharma S.S.; SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: An insight into its mechanism for neuroprotection. Nanomedicine 2013,9(6),776-785","journal-title":"Nanomedicine"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1440-1681.2006.04468.x","volume":"33","author":"Sharma S.","year":"2006","unstructured":"Sharma S.; Kulkarni S.K.; Chopra K.; Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006,33(10),940-945","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/10717544.2014.881438","volume":"21","author":"Zhao X.","year":"2014","unstructured":"Zhao X.; Wang W.; Zu Y.; Zhang Y.; Li Y.; Sun W.; Shan C.; Ge Y.; Preparation and characterization of betulin nanoparticles for oral hypoglycemic drug by antisolvent precipitation. Drug Deliv 2014,21(6),467-479","journal-title":"Drug Deliv"},{"key":"ref=86","first-page":"100181","volume":"13","author":"Qiong Ma L.B.","year":"2021","unstructured":"Qiong Ma L.B.; Zhao X.; Tian X.; Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorated diabetic nephropathy. Mater Today Bio 2021,13,100181","journal-title":"Mater Today Bio"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jconrel.2008.10.002","volume":"133","author":"Li H","year":"2009","unstructured":"Li H; Zhao X; Ma Y; Zhai G; Li L; Lou H; Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009,133(3),238-244","journal-title":"J Control Release"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.3390\/molecules27154980","volume":"27","author":"Kausar M.A.","year":"2022","unstructured":"Kausar M.A.; Anwar S.; Eltayb W.A.; Kuddus M.; Khatoon F.; El-Arabey A.A.; Khalifa A.M.; Rizvi M.R.; Najm M.Z.; Thakur L.; Kar S.; Abdalla M.; MD simulation studies for selective phytochemicals as potential inhibitors against major biological targets of diabetic nephropathy. Molecules 2022,27(15),4980","journal-title":"Molecules"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"110782","DOI":"10.1016\/j.jinorgbio.2019.110782","volume":"199","author":"Martakov I.S.","year":"2019","unstructured":"Martakov I.S.; Shevchenko O.G.; Torlopov M.A.; Gerasimov E.Y.; Sitnikov P.A.; Formation of gallic acid layer on &#x3B3;-AlOOH nanoparticles surface and their antioxidant and membrane-protective activity. J Inorg Biochem 2019,199,110782","journal-title":"J Inorg Biochem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3389\/fphar.2017.01002","volume":"8","author":"Khan T.","year":"2018","unstructured":"Khan T.; Gurav P.; PhytoNanotechnology: Enhancing delivery of plant based anti-cancer drugs. Front Pharmacol 2018,8,1002","journal-title":"Front Pharmacol"},{"key":"ref=91","author":"Mart&#xED;nez-Ballesta M.","year":"2018","unstructured":"Mart&#xED;nez-Ballesta M.; Gil-Izquierdo &#xC1;.; Garc&#xED;a-Viguera C.; Dom&#xED;nguez-Perles R.;  2018"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"P&#xE9;rez-Herrero E","year":"2015","unstructured":"P&#xE9;rez-Herrero E; Fern&#xE1;ndez-Medarde A; Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015,93,52-79","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.2147\/IJN.S213831","volume":"14","author":"Davatgaran Taghipour Y.","year":"2019","unstructured":"Davatgaran Taghipour Y.; Hajialyani M.; Naseri R.; Hesari M.; Mohammadi P.; Stefanucci A.; Mollica A.; Farzaei M.H.; Abdollahi M.; Nanoformulations of natural products for management of metabolic syndrome. Int J Nanomedicine 2019,14,5303-5321","journal-title":"Int J Nanomedicine"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230601163338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217573\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230601163338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:41:58Z","timestamp":1694176918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217573\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450124666230601163338","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}